ライフサイエンスコーパス: intussusception

1 t to be possibly vaccine-related (intestinal intussusception).

2 ds to assess the association between RV1 and intussusception.

3 increased the ability to diagnose or exclude intussusception.

4 ssociation between rotavirus vaccination and intussusception.

5 as negative, positive, or indeterminate for intussusception.

6 ter studies showed a strong association with intussusception.

7 n and safe from the possible complication of intussusception.

8 thheld because of multiple reported cases of intussusception.

9 of a mouse model to study rotavirus-induced intussusception.

10 e risk of the association between RRV-TV and intussusception.

11 ation of the vaccine with the development of intussusception.

12 substantially greater than the rare risk of intussusception.

13 n, adenovirus and HHV-6 were associated with intussusception.

14 xplore here the effect of age on the risk of intussusception.

15 er cuff, the "pluck" technique, and ureteral intussusception.

16 s vaccine (OPV), may also be associated with intussusception.

17 tion between natural rotavirus infection and intussusception.

18 ism by which rotavirus infection could cause intussusception.

19 the rotavirus vaccine and the development of intussusception.

20 ithdrawn after an association was found with intussusception.

21 en suspected of having abnormalities such as intussusception.

22 viruses has been found to be a rare cause of intussusception.

23 virus vaccine suggested an increased risk of intussusception.

24 born at the same hospital as the infant with intussusception.

25 of rotavirus vaccine (Rotashield) and infant intussusception.

26 None of the infants had confirmed intussusception.

27 rtant benefits that outweigh risk related to intussusception.

28 e enough to detect a small increased risk of intussusception.

29 pies, of which two also had small intestinal intussusception.

30 dered in the differential diagnosis of bowel intussusception.

31 contributes to less than 5% of all cases of intussusception.

32 at acted as a leading point to an ileo-ileal intussusception.

33 1 probable, 10 possible and 10 suspected for intussusception.

34 V5 and RV1 outweigh the small excess risk of intussusception.

35 was based on only 12 cases with both CD and intussusception.

36 e small-bowel and 143 (71.5%) were ileocolic intussusceptions.

37 rentiation between ileocolic and small-bowel intussusceptions.

38 An increased risk of intussusception 1 to 7 days after the first dose of RV1

39 There was no increased risk of intussusception 1-7 days after dose 1 (no cases observed

40 Seventy-four of the 429 infants with intussusception (17.2 percent) and 226 of the 1763 contr

41 ed prolonged urine leak (10), infection (6), intussusception (2), and transient renal insufficiency (

42 An increased risk of intussusception 3 to 14 days after the first dose of RRV

43 Intussusception, a condition in which the intestine acut

44 me studies have reported an elevated risk of intussusception, a rare bowel disorder.

45 but on AIN76A diet also developed intestinal intussusception, a tumor-associated pathology in patient

46 , at most, a 7% increase in the incidence of intussusception above the annual background incidence.

47 The total intussusception admission risk attributable to Rotashiel

48 We found no evidence of increased infant intussusception admissions during the period of Rotashie

49 the effect of Rotashield vaccination use on intussusception admissions in ten US states.

50 otashield dose), we estimated an increase in intussusception admissions of 1% (one excess admission)

51 re CD; and a mostly modest increased risk of intussusception after a diagnosis of CD.

52 tatistically significantly increased risk of intussusception after CD diagnosis (hazard ratio=1.95; 9

53 e possibility of a small increase in risk of intussusception after monovalent rotavirus vaccination.

54 7, 1999, after nine cases of infants who had intussusception after receiving the tetravalent rhesus-h

55 work was motivated by the documented risk of intussusception after RotaShield vaccination (Wyeth-Lede

56 ort study in a capture-recapture analysis of intussusception after rotavirus vaccination (RV).

57 new monovalent rotavirus vaccine (RV1) with intussusception after routine immunization of infants in

58 Cases of intussusception after RV were selected from the common t

59 The attributable risk of intussusception after the administration of two doses of

60 The relative incidence of intussusception after the first dose was 0.83 (95% confi

61 There was also an increase in the risk of intussusception after the second dose of the vaccine, bu

62 periods examined, the relative incidence of intussusception after vaccination was unchanged for 18,

63 Unexpected reports of intussusception after vaccination with the live tetraval

64 studies have identified an increased risk of intussusception after vaccination with the second-genera

65 served a significant increase in the rate of intussusception after vaccination, a risk that must be w

66 ing receipt of OPV during the month prior to intussusception among 119 cases and 589 controls matched

67 ntial analyses, we then compared the risk of intussusception among children receiving monovalent rota

68 ring the risk window vs. all other times) of intussusception among infants 28 to 365 days of age with

69 the potential association between RRV-TV and intussusception among infants at least 1 but less than 1

70 We sought to determine the rate of intussusception among infants managed only with short-st

71 Hospital admission for intussusception among infants younger than 365 days of a

72 ociation between vaccination with RRV-TV and intussusception among otherwise healthy infants supports

73 ssibly cause a small increase in the risk of intussusception; an estimated 1-3 US infants out of 100

74 Data were analyzed for 429 infants with intussusception and 1763 matched controls in a case-cont

75 The relation between the risk of intussusception and age at the time of receipt of the fi

76 udies suggest a positive association between intussusception and celiac disease (CD).

77 they assume high vaccine-associated risk of intussusception and do not account for potential herd im

78 We found no association between intussusception and future CD; and a mostly modest incre

79 , surgical reduction, or hospitalization for intussusception and had been enrolled in Medicaid for at

80 RECENT FINDINGS: Intussusception and intestinal malrotation are potential

81 raise their awareness of imaging findings in intussusception and keep in their mind coexistent troubl

82 resence or absence of lymph nodes inside the intussusception and mesentery were noted.

83 ted that it is well tolerated with regard to intussusception and other adverse events and is efficaci

84 avirus vaccine efficacy data, global natural intussusception and regional rotavirus vaccine-related r

85 Loop remodeling occurs also by intussusception and results in the formation of compound

86 idence intervals for the association between intussusception and RV5 by comparing the rates of intuss

87 Adenovirus has been associated with intussusception and slightly increased risk of intussusc

88 The diameters of the intussusception and the inner fat core, the outer bowel

89 s were reviewed to confirm the occurrence of intussusception and the status with respect to rotavirus

90 Potential cases of intussusception and vaccine exposures from 2004 through

91 s US, but also showed additional concomitant intussusceptions and inflamed appendix.

92 ckness was greater than 1.0 in all ileocolic intussusceptions and was less than 1.0 in all small-bowe

93 Revision, Clinical Modification code 560.0 (intussusception) and procedure codes and by review of me

94 , small bowel obstruction, internal hernias, intussusception, and recurrent weight gain.

95 f intussusception, the signs and symptoms of intussusception, and the need for prompt care.

96 described with reference to: the site of the intussusception, and the triggering lesion (either idiop

97 the rate of lipopolysaccharide (LPS)-induced intussusception, and this enhancement was replication de

98 Twenty-nine patients had enteroenteric intussusceptions, and four had intussusceptions involvin

99 ons of these findings on the pathogenesis of intussusception are discussed.

100 Early and subacute cases of intussusception are now ordinarily successfully reduced

101 Intussusceptions are also postulated to result from alte

102 ion is a rare phenomenon, multiple transient intussusceptions are even more uncommon.

103 appendicitis accompanying multiple transient intussusceptions are much more uncommon.

104 = 90 days old accounted for 80% of cases of intussusception associated with a first dose but had rec

105 There was no significantly elevated risk of intussusception associated with receipt of OPV; 9.2% (11

106 We assessed the risk of intussusception associated with Rotarix (RV1) administra

107 at least significantly decrease the risk of intussusception associated with rotavirus vaccination.

108 inistered; this implies an increased risk of intussusception associated with RRV-TV at all ages studi

109 statistically significant increased risk of intussusception associated with RRV-TV for the exposure

110 We found that the incidence of intussusception associated with the first dose of vaccin

111 uted disproportionately to the occurrence of intussusception associated with the use of RotaShield.

112 Prior to identification of the intussusception association (January 1, 1987-July 14, 19

113 t patients with a postoperative diagnosis of intussusception at Mulago National Referral and Teaching

114 thin-walled blood vessels with sprouting or intussusception at the boundary of the ischemic lesion,

115 ion with RRV-TV, we estimated that 1 case of intussusception attributable to the vaccine would occur

116 Vietnam to evaluate infectious etiologies of intussusception before rotavirus vaccine introduction.

117 cessary in a high percentage of infants with intussusception, but does not reduce the incidence of in

118 underestimate the true incidence of level 1 intussusception by >40%.

119 ciation between oral polio vaccine (OPV) and intussusception by linking Scottish vaccination and hosp

120 We assessed the incidence of intussusception by month of life among children <1 year

121 d the age-stratified background incidence of intussusception by use of Healthcare Cost and Utilizatio

122 Because intussusception can be associated with enlargement of gu

123 n upper limit for the attributable risk of 1 intussusception case per 65,287 RV5 dose-1 recipients.

124 red during the study period, with 8 observed intussusception cases (7.11 expected), for a nonsignific

125 rom 2015 to 2017, we enrolled 1-to-1 matched intussusception cases and hospital controls; 249 pairs w

126 m policy considerations, we estimated excess intussusception cases and mortality potentially caused b

127 Analysis was carried out for 466 intussusception cases occurring in 1987-1999 for which l

128 Intussusception cases occurring in infants were identifi

129 se of vaccination far exceeded the number of intussusception cases that may have been associated with

130 e two doses combined, the expected number of intussusception cases was 0.72, resulting in a significa

131 Post-dose 1, there were zero intussusception cases within 1-7 days, and 5 cases withi

132 owing all RV5 doses, we observed 21 cases of intussusception compared with 20.9 expected cases (SIR,

133 were given OPV 0-28 days prior to the case's intussusception date (odds ratio=1.1, 95% confidence int

134 Medicaid for at least 1 month prior to their intussusception date.

135 gastroenteritis deaths prevented per excess intussusception death) and other indicators were calcula

136 ction) and could lead to 201 (77-550) excess intussusception deaths (1.4% increase) compared with no

137 2,000-281,500) while potentially causing 547 intussusception deaths (237-1,160).

138 3,300-217,700) while causing potentially 253 intussusception deaths (76-689).

139 d the second with DTP1 had the fewest excess intussusception deaths and most favourable benefit-risk

140 rotavirus deaths prevented and the number of intussusception deaths caused by vaccination when admini

141 bers of rotavirus gastroenteritis deaths and intussusception deaths in each week of age were calculat

142 astroenteritis deaths and cause fewer excess intussusception deaths than the schedules currently reco

143 3,700) and cause an additional 294 (161-471) intussusception deaths, for an incremental benefit-risk

144 mber the potential excess vaccine-associated intussusception deaths.

145 and clinical records of all patients with an intussusception demonstrated on CT or MR images from Jan

146 Less than one-third of adult intussusceptions demonstrated at CT or MR imaging were c

147 Thirty-three patients had one or more intussusceptions demonstrated on CT (n = 30) or MR (n =

148 n distinguishing the majority of small-bowel intussusceptions detected at CT that are self-limiting f

149 Rotavirus-induced intussusceptions did not have observable lymphoid lead p

150 Excess admissions for intussusception during the period of Rotashield availabi

151 evidence for an association between OPV and intussusception, even when each dose is considered separ

152 ation at ages 2, 4, and 6 months projected 1 intussusception event/11,000-16,000 vaccine recipients;

153 beginning in the neonatal period projected 1 intussusception event/38,000-59,000 vaccine recipients.

154 s, in comparing rotavirus disease averted to intussusception events caused, the hospitalization ratio

155 n has been limited to young infants owing to intussusception events noted with a prior rotavirus vacc

156 ates, because of a temporal association with intussusception events that occurred in vaccinated infan

157 outh America that reported a total of 44,454 intussusception events.

158 Of 156 infants with intussusception fulfilling Brighton level 1 criteria, 81

159 Children with ileocolic intussusception had more severe clinical symptoms and si

160 esus-human reassortant rotavirus vaccine and intussusception has increased the need to develop new va

161 oscopy) in Peutz-Jeghers Syndrome to prevent intussusception have been newly described.

162 ined age-specific trends in population-level intussusception hospitalization rates before (2000-2005)

163 evious rotavirus vaccine, RotaShield, caused intussusception in 1 of every 10,000 recipients, we asse

164 There were 200 cases of intussusception in 174 patients (126 boys, 48 girls; mea

165 rol analysis as well as for 432 infants with intussusception in a case-series analysis.

166 confidence interval: 1,551, 2,025) cases of intussusception in a fully vaccinated, national cohort o

167 Management of intussusception in a pediatric center shows changing pat

168 terval (CI) of each pathogen associated with intussusception in a pooled analysis and quantitative su

169 RV1 was associated with a short-term risk of intussusception in approximately 1 of every 51,000 to 68

170 t of intussusception, we reviewed studies of intussusception in children <18 years of age published s

171 ia that we evaluated was not associated with intussusception in Indian infants.

172 susception and RV5 by comparing the rates of intussusception in infants who had received RV5 with the

173 fants who had received RV5 with the rates of intussusception in infants who received other recommende

174 rotavirus vaccines were not associated with intussusception in large prelicensure trials.

175 ere not associated with an increased risk of intussusception in large trials before licensure, recent

176 A combined annual excess of 96 cases of intussusception in Mexico (approximately 1 per 51,000 in

177 A radiographic modality was used to diagnose intussusception in over 95% of the cases in all regions

178 a causal link between rotavirus vaccines and intussusception in some settings.

179 The risk of intussusception in the 21 days after the first or second

180 The relative risks of intussusception in the periods 3-7 and 8-14 days after R

181 We recorded six cases of intussusception in the vaccine group and two in the plac

182 ors examined the association between OPV and intussusception in the Washington State Medicaid populat

183 nical data for children given a diagnosis of intussusception in the years 2007 through 2011 were eval

184 t to conduct the first review study of adult intussusception in Uganda.

185 us vaccines showed almost identical rates of intussusception in vaccine and placebo recipients.

186 11 (4%), jejunal hematomas in five (2%), and intussusceptions in four (1%).

187 Enteric intussusceptions in the nonneoplastic group were shorter

188 hospital (<365 days old) with any mention of intussusception (International Classification of Disease

189 lastic lead point, including all four of the intussusceptions involving the colon (benign mass, n = 3

190 enteroenteric intussusceptions, and four had intussusceptions involving the colon.

191 Intussusception is a form of intestinal obstruction in w

192 Adult intussusception is a rare clinical condition worldwide.

193 Adult intussusception is a rare phenomenon, acute appendicitis

194 Adult intussusception is a rare phenomenon, multiple transient

195 LPS-induced intussusception is associated with the induction of infl

196 The management of both pediatric and adult intussusception is considered.

197 ted heterotopic pancreas as a cause of bowel intussusception is extremely rare.

198 ding the age period when naturally occurring intussusception is most prevalent (i.e., ages 3-4 months

199 ever, to address the hypothesis that risk of intussusception is related to receipt of a particular do

200 Ileocolic intussusception is the invagination of ileum into the co

201 Adult intussusception is uncommon in the Uganda, though probab

202 Estimates of the risk of intussusception (IS) associated with currently licensed

203 Intussusception (IS) is a form of acute intestinal obstr

204 Seventeen patients had an intussusception length greater than 3.5 cm, as measured

205 Intussusception length is the main factor in distinguish

206 All 20 patients with an intussusception length of 3.5 cm or less, as measured by

207 tepwise, logistic regression analysis showed intussusception length was the only variable that was in

208 The presence of an inner fatty core in the intussusception, lesion diameter, wall thickness, the ra

209 This review of the intussusception literature from the past decade provides

210 five surgically confirmed masses (carcinoid, intussusception, lymphangioma) were identified, but two

211 ortality by week of age from a recent study, intussusception mortality based on a literature review,

212 ccines with regard to the associated risk of intussusception must be demonstrated as well.

213 We present a case of an ileocolic intussusception necessitating surgery in a 7-month-old i

214 evious rotavirus vaccine was associated with intussusception, new rotavirus vaccines are monitored po

215 um schedule to avoid or significantly reduce intussusception, now reported to be associated in intern

216 a) and used worldwide spontaneous reports of intussusception occurring after Rotarix vaccination (Gla

217 Intussusception occurring in the 1- to 7-day and 1- to 3

218 helial polarity and proliferation leading to intussusception of endothelial cells and extensive remod

219 gation provide support for the idea that the intussusception of newly secreted pectin contributes to

220 There were 5 deaths due to pneumonia (n=1), intussusception of the graft (n=1), cardiorespiratory ar

221 yses regarding the dependence of the risk of intussusception on age at first dose.

222 and quiting imaging studies after finding an intussusception on ultrasound, may lead diagnostic error

223 Wild-type rotavirus was not associated with intussusception (OR, 1.07; 95% CI, 0.52-2.22).

224 20 quantification cycles was associated with intussusception (OR, 18.59; 95% CI, 2.45-140.89).

225 1.42 cm (range, 0.8-3.0 cm) for small-bowel intussusception (P < .0001).

226 us 0.1 cm (range, 0-0.75 cm) for small-bowel intussusception (P < .0001).

227 ersus in eight (14.0%) of the 57 small-bowel intussusceptions (P < .0001).

228 ons and was less than 1.0 in all small-bowel intussusceptions (P < .0001).

229 d to better understand mechanisms leading to intussusception, particularly after rotavirus vaccinatio

230 l evaluation of patients suspected of having intussusception, particularly when the supine view is di

231 The number of excess cases of intussusception per 100,000 recipients of the first dose

232 ely 1.5 (95% CI, 0.2 to 3.2) excess cases of intussusception per 100,000 recipients of the first dose

233 to identify an array of diseases, including intussusception, pyloric stenosis and appendicitis.

234 Six possible risk periods for intussusception, ranging from 3 days after vaccination t

235 The mean annual intussusception rate for the hospitals' catchment counti

236 Accurate background intussusception rates are needed to determine whether th

237 Intussusception rates based solely on inpatient discharg

238 the induction of inflammatory mediators, and intussusception rates can be modified by inflammatory an

239 us vaccine introduction, a small increase in intussusception rates was seen among US infants aged 8-1

240 Previously, intussusception rates were obtained from inpatient disch

241 fects of subsequent LPS treatment to enhance intussusception rates.

242 Treatment did not involve intussusception reduction in 14 patients (37.8%).

243 traperitoneal hemorrhage; the second died of intussusception-related bowel necrosis 10 days after TEP

244 d internationally, to further quantitate the intussusception risk following each vaccine.

245 No increase in intussusception risk was found in the case-control analy

246 Although US data have not documented an intussusception risk with current rotavirus vaccines, in

247 s of vaccine efficacy and vaccine-associated intussusception risk.

248 e potential mortality reduction benefits and intussusception risks of current rotavirus vaccination s

249 Mortality reduction benefits and intussusception risks of rotavirus vaccination were mode

250 Ambulatory or nonhospital management of intussusception subjects the infant to the risk of a sig

251 this review relates to the heterogeneity in intussusception surveillance across different regions.

252 ion that should facilitate implementation of intussusception surveillance for monitoring the postlice

253 esection of the ureteral orifice (pluck) and intussusception techniques should be approached with cau

254 An intussusception that is shorter than 3.5 cm is likely to

255 t was self-limiting, and six patients had an intussusception that required surgery.

256 abdominal CT not only confirmed the enteric intussusception that was demonstrated on previos US, but

257 Eleven patients had an intussusception that was self-limiting, and six patients

258 The etiology of intussusception, the leading cause of bowel obstruction

259 oviders should be aware of the small risk of intussusception, the signs and symptoms of intussuscepti

260 To minimize potential risk of intussusception, the World Health Organization (WHO) rec

261 ants are relatively refractory to developing intussusception, thereby avoiding the age period when na

262 isting with multiple spontaneously resolving intussusceptions, to the literature.

263 tic assumptions about access to hospital for intussusception treatment (168:1).

264 000 each in order to address questions about intussusception triggered by a third earlier vaccine.

265 ere seen in 128 (89.5%) of the 143 ileocolic intussusceptions versus in eight (14.0%) of the 57 small

266 rrent period and with the expected number of intussusception visits based on background rates assesse

267 .12%) individuals with CD had a diagnosis of intussusception vs. 143 (0.10%) reference individuals, s

268 CD in patients with at least two records of intussusception was 0.40 (95% CI=0.06-2.99).In contrast,

269 The mean incidence of intussusception was 74 per 100,000 (range: 9-328) among

270 as most favourable when the relative risk of intussusception was assumed to decline with the national

271 1 per 68,000 infants) and of 5 deaths due to intussusception was attributable to RV1.

272 Active prospective surveillance for intussusception was conducted in 8 hospitals from Septem

273 Intussusception was correctly excluded with the KUB view

274 Intussusception was correctly identified with KUB view a

275 Moreover, the frequency of intussusception was increased when the compound mutant m

276 Each infant with intussusception was matched according to age with four h

277 .10%) reference individuals, suggesting that intussusception was not a risk factor for later CD (OR=1

278 4 to 34 weeks who received RV5, the risk of intussusception was not increased compared with infants

279 Intussusception was present in 58 of 304 studies (19%).

280 ccination was associated with 1,400 cases of intussusception, was $36 (95% confidence interval: $28,

281 background rates and clinical management of intussusception, we reviewed studies of intussusception

282 dies and the ability to visualize or exclude intussusception were calculated to determine sensitivity

283 rough June 2019, a total of 970 infants with intussusception were enrolled, and 589 infants who were

284 ia of radiologic or surgical confirmation of intussusception were enrolled, and rotavirus vaccination

285 ratios (ORs) for future CD in patients with intussusception were estimated using conditional logisti

286 Thirty-seven cases of adult small-bowel intussusception were identified by a retrospective compu

287 Cases of intussusception were identified from nationwide inpatien

288 Infants with intussusception were identified through active surveilla

289 ccine was withdrawn when reports of cases of intussusception were linked to recent vaccination.

290 drawn in 1999 due to a rare association with intussusception, which occurred disproportionately in in

291 vaccines are introduced globally, monitoring intussusception will be crucial for ensuring safety of t

292 tussusception and slightly increased risk of intussusception with rotavirus vaccination has been foun

293 nsure identification of an increased risk of intussusception with rotavirus vaccine, the 14 Latin Ame

294 statistically significant increased risk of intussusception with RV5 for either comparison group fol

295 after studies observed an increased risk of intussusception within 2 weeks after immunization.

296 The relative risk of chart-confirmed intussusception within 7 days after monovalent rotavirus

297 We reviewed medical records and visits for intussusception within 7 days after monovalent rotavirus

298 We identified 6 cases of intussusception within 7 days after the administration o

299 1-3 US infants out of 100 000 might develop intussusception within 7 days of getting their first dos

300 d be useful in assessing whether the risk of intussusception would be similar to the risk seen with d

301 126-293) and 10 deaths (90% CI, 6-17) due to intussusception, yielding benefit-risk ratios for hospit